Follow Up Treatment Articles & Analysis
19 news found
The primary safety endpoint is the rate of Major Adverse Events (MAEs), including device-related death and major bleeding within the first 48 hours. Patients will be followed for 30 days post-index procedure. “The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary ...
The day after the procedure, the patients were examined by magnetic resonance imaging for signs of small strokes triggered by the treatment and then followed up for one year. As a result, the group that received 120 milligrams of Revacept had only about half as many small strokes as the placebo group. ...
Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting. ...
Relief can last anywhere from a few days up to a full year after treatment. This gives the patient time to recover from their injury by engaging in helpful rehab movements. ...
(TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment option for patients ...
The feedback collected speaks to us of patients who feel involved, engaged, followed, monitored and protected. In fact, the platform also allows access via application to the patient who, once entered in the program, will receive devices useful for measurements. Being at home but feeling monitored, followed and guided in the ...
ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable embolic therapies, announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in ...
In the cohort followed through two years, HbA1c was observed to be statistically significantly reduced at all time points, as were broader measures of metabolic control, including reductions in weight and improvements in patient self-reported diabetes treatment satisfaction questionnaires (DTSQc). ...
As Kadimastem intends to submit the IND for the Phase IIa clinical study before the end of 2022, the IIA funding will be used to scale up the production of a frozen, off-the-shelf product of AstroRx® in preparation for the trial. ...
Patients will receive a single Eye90 microspheres radioembolization treatment with follow-up visits for one year to assess safety, effectiveness, and quality of life measures. ...
LYR-210 is highly convenient to administer and remove in a routine office visit and has the potential to provide an impactful treatment option for a broad CRS patient population." "The LANTERN follow-up and PK data presented at ARS underscore our belief in LYR-210's potential to disrupt the CRS treatment landscape for the ...
In the pilot analysis, patients with follow-up showed Bladder EpiCheck achieved 100% sensitivity for high-grade disease, with specificity of 88%, thereby avoiding 76% of unnecessary cystoscopies. ...
Taking directed tissue samples helps doctors and patients and arrange for follow up treatment sooner rather than later. A patient can have increased confidence in their diagnosis while the simplicity of the equipment makes the procedure more convenient and less challenging for the physician. ...
“Carillon provides an option to treat a large portion of FMR patients with a minimally-invasive treatment that doesn’t compromise the valve leaflets. Patients across a wide spectrum of MR grade and NYHA class benefited from Carillon treatment, experiencing significant improvements in MR and favorable remodeling of the left ventricle. ...
Less radiant, this system is in line with our efforts to reduce children's exposure to X-rays during the follow-up and treatment of scoliosis. Protected by over thirty patents, Surgivisio’s technology enabled the company to win phases 1, 2 and 3 of the World Innovation Challenge, and to benefit from an investment in 2018 of 10.7 million ...
It’s also radiolucent, allowing for real-time monitoring of bone tissue regeneration during the follow up phases of the fusion treatment. Orthopedic surgeons across the United States are showing interest in the product’s unique array of characteristics. ...
Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful first-in-human implantation of its Alivio ReFlow™ Ventricular System for treatment of hydrocephalus at Boston Children’s Hospital. ...
The new company, known as Anuncia, Inc., is an independent company focused on better treatment of Hydrocephalus and cerebrospinal fluid dysfunctions. The separation and spin-off of Anuncia from Alcyone comes on the heels of receiving the EU CE Mark and US FDA Clearance of ReFlow Ventricular System for the treatment of hydrocephalus. ...
Rengaswamy Sankaranarayanan, was designed to assess the effectiveness of various cervical cancer screening technologies in reducing cervical cancer incidence and death rates. Following the April 2009 publication of study results in The New England Journal of Medicine, QIAGEN announced a donation of one million HPV tests to low-income countries over five years. ...